# Chemomab (CMMB) — News

CMMB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cmmb/news

## Recent headlines

- [L&T to report Q2 results on Oct. 27](https://www.ainvest.com/news/report-q2-results-oct-27-2610) — AInvest Wire, Oct 13, 2026
- [EU clears acquisition of BTZ by CM and Bunge](https://www.ainvest.com/news/eu-clears-acquisition-btz-cm-bunge-2610) — AInvest Wire, Oct 13, 2026
- [Chemomab Therapeutics Ltd - Unit signs amendment no. 1 to merger agreement with Scipher Medicine - SEC filing](https://www.ainvest.com/news/chemomab-therapeutics-unit-signs-amendment-1-merger-agreement-scipher-medicine-sec-filing-2610) — AInvest Wire, Sep 30, 2026
  Chemomab Therapeutics Ltd has executed Amendment No. 1 to its merger agreement with Scipher Medicine, as disclosed in a recent SEC filing. The amendment outlines adjustments to the terms of the proposed business combination, reflecting ongoing strategic considerations and regulatory developments.…
- [Chemomab Therapeutics Ltd - Nebokitug RA Phase 2 clinical trial expected to begin in H1 2027 and read out in H1 2028](https://www.ainvest.com/news/chemomab-therapeutics-nebokitug-ra-phase-2-clinical-trial-expected-h1-2027-read-h1-2028-2608) — AInvest Wire, Aug 19, 2026
- [Chemomab Therapeutics Q2 EPS USD -0.003](https://www.ainvest.com/news/chemomab-therapeutics-q2-eps-usd-0-003-2608) — AInvest Wire, Aug 19, 2026
  Chemomab Therapeutics Ltd. (CMMB) reported an EPS of -USD 0.003 for the second quarter of 2025, reflecting continued financial challenges for the biopharmaceutical company based in Tel Aviv, Israel. The company’s cash and cash equivalents declined from $6.07 million at the end of 2024 to $5.45…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).